CLK kinase inhibitors (Brickell Biotech)

N/A

Report date: 2025/03/14 16:24:52
NME

Base Information

Drug NameCLK kinase inhibitors (Brickell Biotech)
Drug Alias NameCLK kinase inhibitors (Fresh Tracks Therapeutics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionClk dual-specificity kinase inhibitors
TargetsDual specificity protein kinase CLK
Therapy Area/IndicationsInflammationAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFresh Tracks Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesFresh Tracks Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsInflammationAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A